Crinetics Q1 net loss $96.8M; cash $1.3B; paltusotine PDUFA Sept 25, 2025

Crinetics Pharmaceuticals, Inc.

2025-Q1 EPS reported -$1.04 revenue$361,000

Net loss of $96.8M for Q1 2025 vs. $66.9M in Q1 2024, driven by higher R&D and SG&A costs.
Revenue $0.4M, down from $0.6M; primarily from Sanwa Kagaku licensing agreement.
Cash, equivalents, and investments $1.3B, expected to fund operations into 2029.
Paltusotine NDA under FDA review with PDUFA target action date Sept 25, 2025.
Phase 3 CALM-CAH study of atumelnant in CAH to begin H2 2025; R&D Day June 26.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.